What is Cybergenetics?
Cybergenetics operates at the intersection of advanced genomics and computational science, providing sophisticated software tools that resolve complex DNA data. The company's flagship technology, TrueAllele, represents a paradigm shift in probabilistic genotyping, enabling the transformation of previously uninterpretable forensic evidence into definitive identification metrics. Beyond its core forensic applications, the firm has expanded its operational footprint with the ORCA platform, a specialized intelligence tool engineered to assist loss prevention professionals in mitigating retail theft through rapid crime scene DNA identification. With a legacy spanning over two decades, Cybergenetics maintains a dominant market position by bridging the gap between raw biological data and actionable intelligence for law enforcement and clinical stakeholders.
How much funding has Cybergenetics raised?
Cybergenetics has raised a total of $300K across 2 funding rounds:
Debt
$150K
Debt
$150K
Debt (2020): $150K with participation from PPP
Debt (2021): $150K led by PPP
Key Investors in Cybergenetics
PPP
Public-Private Partnership
What's next for Cybergenetics?
With the successful acquisition of this late-stage capital, Cybergenetics is well-positioned to accelerate the deployment of its DNA intelligence platforms across global markets. The strategic focus will likely shift toward enhancing the scalability of the ORCA ecosystem and deepening the integration of TrueAllele within international judicial frameworks. As the demand for objective, automated forensic analysis continues to rise, the company is poised to leverage its technical expertise to set new benchmarks in genomic accuracy. Future initiatives will likely prioritize the expansion of its research and development pipeline, ensuring that its software remains at the vanguard of forensic science while addressing emerging challenges in retail security and personalized medicine.
See full Cybergenetics company page
